Streetbeat News

Revenues

DOCS

In the last three months, 8 analysts have shared their evaluations of Doximity (NYSE:DOCS), revealing diverse outlooks. The average 12-month price target has risen by 8.51% to $31.0. Analysts have adjusted their ratings and price targets, with some raising and others lowering their expectations. Doximity has shown strong financial performance with impressive revenue growth, net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

August 14, 2024 | 3:00 pm

MRK

The article provides an in-depth analysis of Merck & Co (NYSE:MRK) compared to its competitors in the Pharmaceuticals industry. It highlights Merck's lower P/E, P/B, and P/S ratios, suggesting potential undervaluation. However, Merck's lower ROE, EBITDA, gross profit, and revenue growth indicate weaker financial performance relative to its peers. The company's lower debt-to-equity ratio suggests a stronger financial position.

Portfolio Pulse from Benzinga Insights

August 14, 2024 | 3:00 pm

COST

The article provides a comprehensive comparison of Costco Wholesale (NASDAQ:COST) with its key competitors in the Consumer Staples Distribution & Retail industry. It highlights Costco's high P/E, P/B, and P/S ratios, suggesting potential overvaluation. However, Costco's strong ROE and revenue growth indicate robust performance. The company's lower EBITDA and gross profit raise concerns about operational efficiency. Costco's lower debt-to-equity ratio suggests a stronger financial position compared to its peers.

Portfolio Pulse from Benzinga Insights

August 14, 2024 | 3:00 pm

TSAT

Telesat (NASDAQ:TSAT) shares surged after the company reported stronger-than-expected Q2 2024 results. Despite a 15.2% YoY revenue decline to C$152.44 million, the figure beat the consensus estimate of C$141.15 million. EPS was C$2.45, above the consensus estimate of C$1.71. The company remains on track to meet its 2024 guidance, with expected revenues between C$545 million and C$565 million and Adjusted EBITDA between C$340 million and C$360 million.

Portfolio Pulse from Akanksha Bakshi

August 14, 2024 | 2:54 pm

BTCUSD

Bitcoin miners are expanding their operations as the network's hashrate hits a new record of 627 exahash per second, despite a recent price drop and low hash price. This indicates optimism among miners after a phase of selling. Miner outflows surged recently, suggesting squeezed profit margins.

Portfolio Pulse from Murtuza Merchant

August 14, 2024 | 2:47 pm

HD

TGT

WMT

Home Depot (HD) reported fiscal Q2 earnings and sales that topped estimates but warned of declining annual profit and comparable sales due to weak discretionary spending. Revenue rose to $43.18 billion, but net income fell to $4.56 billion. Comparable sales dropped 3.3%, marking the seventh consecutive quarter of negative comparable sales. Home Depot expects annual comparable sales to drop 3-4% YoY and diluted profit per share to drop 2-4%. The SRS Distribution deal is expected to boost annual sales by $6.4 billion. Investors are now looking to Walmart (WMT) and Target (TGT) for further consumer health insights.

Portfolio Pulse from Upwallstreet

August 14, 2024 | 2:35 pm

COP

ConocoPhillips (NYSE:COP) has outperformed the market over the past 5 years, delivering an average annual return of 15.58%. A $100 investment in COP 5 years ago would now be worth $201.56. The article highlights the impact of compounded returns on investment growth.

Portfolio Pulse from Benzinga Insights

August 14, 2024 | 2:31 pm

CCI

Crown Castle (NYSE:CCI) has outperformed the market over the past 20 years with an average annual return of 10.99%, resulting in a $1000 investment growing to $8,060.07. The company currently has a market capitalization of $48.07 billion.

Portfolio Pulse from Benzinga Insights

August 14, 2024 | 2:30 pm

SPY

USO

The EIA reported a weekly draw in distillate stocks of 1.673 million barrels, which is less than the estimated draw of 1.800 million barrels. This follows a prior build of 0.949 million barrels.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 2:30 pm

LLY

NVO

PFE

Eli Lilly (LLY) reported outstanding Q2 results, driven by high demand for its diabetes and weight loss drugs, Mounjaro and Zepbound. Revenue rose 36% to $11.30 billion, and net income surged to $2.97 billion. The company also raised its full-year guidance. In contrast, Novo Nordisk (NVO) reported weaker sales due to price concessions. Pfizer (PFE) is still struggling to enter the weight loss market.

Portfolio Pulse from Upwallstreet

August 14, 2024 | 2:26 pm